PRIMIER: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI‐724 as First Line Treatment for Metastatic Colorectal Cancer

Trial Profile

PRIMIER: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI‐724 as First Line Treatment for Metastatic Colorectal Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs PRI 724 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PRIMIER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Study drug supply issues.
    • 24 Sep 2015 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top